Table 1 Univariate and multivariate analysis of overall survival in 82 patients

From: A proteomic landscape of diffuse-type gastric cancer

Variable (n)

Univariate analysis

Multivariate analysis

 

HR (95% CI)

P-value

HR (95% CI)

P-value

Agea

1.037 (1.001–1.076)

0.045

1.033 (0.994–1.074)

0.102

Gender

    

 Male (51)

1.0

   

 Female (31)

1.122 (0.478–2.638)

0.791

  

Adjuvant chemotherapy

    

 Without (21)

1.0

 

1.0

 

 Withb (61)

0.330 (0.138–0.788)

0.009

0.834 (0.282–2.466)

0.742

Tumor site

    

 Cardia, GEJ (20)

1.0

   

 Body (33)

1.405 (0.439–4.501)

0.567

  

 Antrum (29)

1.497 (0.450–4.986)

0.511

  

Clinical stagea

    

 (Ib to IV)

7.065 (2.661–18.760)

<0.001

17.91 (3.529–90.91)

<0.001

TP53 mutation

    

 Wild type (45)

1.0

   

 Mutant (37)

1.407 (0.608–3.260)

0.423

  

Profiling cluster

    

 PX1 (17)

1.0

 

1.0

 

 PX2 (32)

2.186 (0.453–10.560)

0.330

4.280 (0.731–25.052)

0.107

 PX3 (34)

4.221 (0.950–18.760)

0.058

9.785 (1.597–59.935)

0.014

 P trend

2.009 (1.070–3.772)

0.025

2.757 (1.329–5.722)

0.006

  1. GEJ, gastroesophageal junction; HR, hazard ratio; CI, confidence interval
  2. aContinuous variable
  3. bPatients proceed through at least one cycle of adjuvant chemotherapy. Significant data are emphasized in bold
Back to article page